Korean biotech’s shares soar for a 'best of ESMO' award it never received
A Korean biotech announced in October it had earned recognition on a “Best of ESMO 2019” list – a fact that turned out to be news to ESMO.
The European Society for Medical Oncology said yesterday that the biotech, HLB, did not win an award but rather was one in a list of conference highlights that had shown “interesting results,” Bloomberg reported. HLB’s stock — which had doubled in value on the heels of their ESMO recognition — began to trickle down.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.